ALX Oncology Holdings Inc logo

ALXO - ALX Oncology Holdings Inc Share Price

$44 0.7  1.7%

Last Trade - 7:41pm

Market Cap £1.20bn
Enterprise Value £1.26bn
Revenue £3.37m
Position in Universe 1984th / 6368
Bullish
Bearish
Unlock ALXO Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -13.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 2.07 4.80 +132%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2020, ALX Oncology Holdings Inc revenues decreased 37% to $655K. Net loss applicable to common stockholders increased 45% to $7.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects General and administrative - Balancing increase from $581K to $1.4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ALXO Revenue Unlock ALXO Revenue

Net Income

ALXO Net Income Unlock ALXO Revenue

Normalised EPS

ALXO Normalised EPS Unlock ALXO Revenue

PE Ratio Range

ALXO PE Ratio Range Unlock ALXO Revenue

Dividend Yield Range

ALXO Dividend Yield Range Unlock ALXO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ALXO EPS Forecasts Unlock ALXO Revenue
Profile Summary

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company. The Company is focused on enabling patients to fight cancer by developing therapies that block the cluster of differentiation 47 (CD47) checkpoint pathway and bridge the innate and adaptive immune system. The Company is developing a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Its lead product candidate, ALX148, is a CD47 blocking therapeutic. ALX148 is a fusion protein that combines a CD47 binding domain with its inactivated fragment crystallizable (Fc) domain. The CD47 binding domain of ALX148 is an affinity enhanced extracellular domain of signal regulatory protein alpha (SIRPa), a protein that is the natural receptor to CD47 found on myeloid cells. Its programs are focused on targeting CD47 across various oncology indications.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
No. of Shareholders: n/a
No. of Employees: 24
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 36,486,553
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ALXO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ALXO
Upcoming Events for ALXO
Frequently Asked Questions for ALX Oncology Holdings Inc
What is the ALX Oncology Holdings Inc share price?

As of 7:41pm, shares in ALX Oncology Holdings Inc are trading at $44, giving the company a market capitalisation of £1.20bn. This share price information is delayed by 15 minutes.

How has the ALX Oncology Holdings Inc share price performed this year?

Shares in ALX Oncology Holdings Inc are currently trading at $44 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the ALX Oncology Holdings Inc price has moved by % over the past year.

What are the analyst and broker recommendations for ALX Oncology Holdings Inc?

There are no analysts currently covering ALX Oncology Holdings Inc.

When will ALX Oncology Holdings Inc next release its financial results?

ALX Oncology Holdings Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the ALX Oncology Holdings Inc dividend yield?

ALX Oncology Holdings Inc does not currently pay a dividend.

Does ALX Oncology Holdings Inc pay a dividend?

ALX Oncology Holdings Inc does not currently pay a dividend.

When does ALX Oncology Holdings Inc next pay dividends?

ALX Oncology Holdings Inc does not currently pay a dividend.

How do I buy ALX Oncology Holdings Inc shares?

To buy shares in ALX Oncology Holdings Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of ALX Oncology Holdings Inc?

Shares in ALX Oncology Holdings Inc are currently trading at $44, giving the company a market capitalisation of £1.20bn.

Where are ALX Oncology Holdings Inc shares listed? Where are ALX Oncology Holdings Inc shares listed?

Here are the trading details for ALX Oncology Holdings Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ALXO
What kind of share is ALX Oncology Holdings Inc?

Based on an overall assessment of its quality, value and momentum, ALX Oncology Holdings Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a ALX Oncology Holdings Inc share price forecast 2020?

We were not able to load any forecast data for ALX Oncology Holdings Inc.

How can I tell whether the ALX Oncology Holdings Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ALX Oncology Holdings Inc. Over the past six months, the relative strength of its shares against the market has been %. At the current price of $44, shares in ALX Oncology Holdings Inc are trading at 32.41% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the ALX Oncology Holdings Inc PE Ratio?

We were not able to find PE ratio data for ALX Oncology Holdings Inc.

Who are the key directors of ALX Oncology Holdings Inc?

We were unable to find the directors for ALX Oncology Holdings Inc.

Who are the major shareholders of ALX Oncology Holdings Inc?

Here are the top five shareholders of ALX Oncology Holdings Inc based on the size of their shareholding:

VenBio Partners LLC Private Equity
Percentage owned: 24.1% (8.79m shares)
Lightstone Ventures, L.P. Corporation
Percentage owned: 12.94% (4.72m shares)
Vivo Capital, LLC Venture Capital
Percentage owned: 11.57% (4.22m shares)
Logos Global Management LLC Investment Advisor
Percentage owned: 5.88% (2.14m shares)
Pons (Jaume) Individual Investor
Percentage owned: 1.56% (568k shares)
Similar to ALXO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.